Q² Solutions partners with the Coalition for Epidemic Preparedness Innovation (CEPI)

Joins global network to reliably assess and compare the immunological responses generated by COVID-19 vaccine candidates


Morrisville, NC – October 21, 2020 – Q2 Solutions, a leading clinical trial laboratory services organization, announced today a partnership with the Coalition for Epidemic Preparedness Innovation (CEPI) to harmonize evaluation of multiple COVID-19 vaccine candidates undergoing preclinical and clinical (up to Phase II) testing across the globe.  

Q2 Solutions was selected to partner with CEPI along with six other laboratories. These laboratories are located across multiple regions globally and include: Nexelis (Canada) and Public Health England (PHE, UK), VisMederi Srl (Italy), Viroclinics-DDL (The Netherlands), icddr,b (formerly International Centre for Diarrhoeal Disease Research, Bangladesh), and Translational Health Sciences and Technological Institute (THSTI, India). The network will drive utilization of the same testing reagents and follow common protocols to measure the immunogenicity of multiple COVID-19 vaccine candidates (both CEPI-funded and non-CEPI funded developers). This approach will ensure uniformity in assessment and informed identification of the most promising vaccine candidates. 

“We are honored to be selected as one of the laboratories involved in the CEPI network, as we work as a team to fight against COVID-19,” said Kevin Jones, vice president, general manager, Bioanalytical, ADME, and Vaccines Services, for Q2 Solutions. “We are committed to be a collaborative partner, utilizing our talents, resources and comprehensive portfolio of assays to serve the greater cause we all work for, to the benefit of the health and well-being of people across the globe.”

About Q2 Solutions
Q2 Solutions is a leading global clinical trial laboratory services organization providing comprehensive testing, project management, supply chain, biorepository, biospecimen and consent tracking solutions. Leveraging our next generation technologies, we deliver agile and precise services designed to meet the diverse needs of our clients. We provide scientific expertise and innovative solutions for ADME, bioanalytical, genomics, vaccines and central laboratory services, including flow cytometry, anatomic pathology, immunoassay, molecular and companion diagnostics, with meticulous regional and global clinical trial implementation support and high-quality data delivery. At Q2 Solutions, our work is rooted in research, grounded in collaboration, and guided by our passion to turn the hope of patients and caregivers around the world into the help they need. To learn more, visit  

About CEPI
CEPI is an innovative partnership between public, private, philanthropic, and civil organizations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID-19. CEPI has initiated nine partnerships to develop vaccines against the novel coronavirus. The programs are leveraging rapid response platforms already supported by CEPI as well as new partnerships. Before the emergence of COVID-19, CEPI’s priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X). Follow our news page for the latest updates.